Amicus Therapeutics Commences Phase 1/2 Study of Novel ERT for Treatment of Pompe Disease
CRANBURY, N.J., Dec. 22, 2015 (GLOBE NEWSWIRE)—Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of rare and orphan diseases, today announced that its investigational new drug (IND) application, submitted to U.S. Food and Drug...
2015 Helen Walker Research Grant Awarded
The sixth annual AMDA Research Grant (the 2015 Helen Walker Research Grant) was awarded to Dr. Rosa Puertollano and Dr. Nina Raben for their Project: “Curcumin: Can it promote cellular clearance in Pompe disease?.” The aim of this project is to test the possibility of...
2015 AMDA International Pompe Patient and Scientific Conference-Update
For the twentieth (20th) anniversary of the AMDA, we will be hosting an International Patient and Scientific Conference in San Antonio, Texas from October 30, 2015 - November 1, 2015. The Conference will begin on Friday evening (October 30th) with a Welcome Dinner,...
2015 Helen Walker Research Grant for Pompe Disease Now Accepting Applications
The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe Disease research. This grant opportunity was made possible by a fundraiser hosted by the Precast Manufacturer’s Association of Texas (PCMA of Texas) on April 18,...
Registration now open for 2015 AMDA International Pompe Patient and Scientific Conference
We are excited to announce that Registration is now open for the 2015 AMDA International Pompe Patient and Scientific Conference! The Conference will be held in San Antonio, Texas from October 30-November 1, 2015. In order to assist with Conference planning, we ask...
Genzyme’s Pompe Community Program Update for International Pompe Day
Please click here to read the press release.
Pompe Program to Air on Lifetime’s Access Health on April 15, 2015
The AMDA is excited to announce that in collaboration with Genzyme Corporation, AMDA President and IPA Chair, Tiffany House, participated in a segment on Pompe Disease awareness for Access Health on Lifetime Television! This program will air on April 15th, 2015 in...
Pompe Disease to be Added to Recommended Newborn Screening Panel in the United States
The AMDA is very excited to announce that the U.S. Pompe Community is one step closer to having newborn screening become a reality for Pompe disease! On March 2, 2015, the Secretary of Health and Human Services, Sylvia Burwell, accepted the recommendation to add Pompe...
Date Set for 5th Annual PCMA of Texas’ Pull for Pompe!
The PCMA of Texas invites you to enjoy a day of family fun benefiting Acid Maltase Deficiency, also known as Pompe Disease. This event is designed for all ages and ability levels. It will be held at the National Shooting Complex in San Antonio, Texas. Please click...
Australian Pompe’s Association Welcomes Approval of Treatment for Young Australians with Pompe
Press Release by Australian Pompe Association (APA) 17th February 2015 The Australian Pompe’s Association (APA) welcomes the news that the Minister for Health Sussan Ley has approved treatment for young Australians with Pompe disease. As of the 1st February 2015, the...
Second Annual International Pompe Day!
April 15th, 2015 will mark the Second Annual International Pompe Day! Last year the Pompe Community worked together to raise awareness of Pompe Disease, and showed the world how Strong our Community can be. Please click here for a summary of the events and activities...
Update on Biomarin’s Pompe Clinical Program—January 2015
BioMarin are pausing further recruitment for their BMN-701 clinical trial and have provided this programme update: January 2015 BioMarin is pleased to update the Pompe patient community on the progress made in our programme to develop a treatment for people living...
2014 Helen Walker Research Grant Awarded
The fifth annual AMDA Research Grant (the 2014 Helen Walker Research Grant) was awarded to Dr. Giancarlo Parenti with the Federico II University in Naples, Italy for his Project: “Analysis of Circulating and Tissue Specific microRNAs in Pompe Disease.” Despite...
Design And Performance Of Clinical Trials: An Overview
Title: Design and Performance of Clinical Trials: An Overview
Date: Monday, October 20, 2014
Speaker:
Anne Zajicek, MD, PharmD, FAAP, Chief, Obstetric and Pediatric, Pharmacology and Therapeutics Branch, National Institute of Child Health and Human Development (NICHD)
United States Pompe Community Update from Genzyme
Genzyme would like to share with you an important update regarding the recent United States (U.S.) Food and Drug Administration’s (FDA) approval of an expanded label for Lumizyme® (alglucosidase alfa) manufactured at the 4000L scale and its impact on Myozyme®...
FDA and Genzyme Announce Label Expansion of Lumizyme in United States
To the United States Pompe Community: On August 1, 2014 the US Food and Drug Administration (FDA) and Genzyme issued press releases regarding the expansion of the Lumizyme® label (the enzyme replacement therapy for Pompe disease produced at the 4000L manufacturing...
2014 Helen Walker Research Grant Now Accepting Applications
The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe Disease research. This grant opportunity was made possible by a fundraiser hosted by the Precast Manufacturer’s Association of Texas (PCMA of Texas) on April 5,...
BioMarin Doses First Patient in Phase 3 INSPIRE Trial with BMN 701 for the Treatment of Pompe
San Rafael, Calif., May 27, 2014 – BioMarin Pharmaceutical Inc. announced today that it has dosed the first patient with BMN 701 (GILT-tagged Recombinant Human GAA) in the Phase 3 INSPIRE trial for Pompe disease. BMN 701 is a novel fusion protein of insulin-like...
AMDA to Celebrate First International Pompe Day!!
Update: May 4, 2014 THE AMDA TO CELEBRATE THE FIRST INTERNATIONAL POMPE DAY WITH COMMEMORATIVE BOOK April 15, 2014 marked the International Pompe Association’s (IPA) first annual International Pompe Day. In honor of the First International Pompe Day, the Acid Maltase...
The Contribution Of The IPA Survey To Our Understanding Of The Natural Course Of Pompe Disease
Title: The contribution of the IPA survey to our understanding of the natural course of Pompe disease and effects of enzyme therapy: Ten years of the IPA survey
Date: Thursday, February 27, 2014
Speaker:
J.C. van der Meijden, Center for Lysosomal and Metabolic diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands
Webinar Overview:
For more than ten years Pompe patients, from all over the world, participate in the International Pompe Association / Erasmus MC Pompe survey on a yearly basis. During this period we have gathered a vast amount of information on the natural course of Pompe disease and the effects of enzyme replacement therapy. During this webinar we will discuss what we have learned about Pompe disease by working with the Survey. Furthermore, we will discuss the importance of the survey and goals for the future. At the last part of the webinar there is an opportunity for participants to ask questions to the researchers.